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Current influenza vaccines mostly aim at the induction of specific neutralizing antibodies.
While antibodies are important for protection against a particular virus strain, T cells can
recognize epitopes that will offer broader protection against influenza. We have previously
developed a DNA vaccine format by which protein antigens can be targeted specifically
to receptors on antigen presenting cells (APCs). The DNA-encoded vaccine proteins
are homodimers, each chain consisting of a targeting unit, a dimerization unit, and an
antigen. The strategy of targeting antigen to APCs greatly enhances immune responses
as compared to non-targeted controls. Furthermore, targeting of antigen to different
receptors on APCs can polarize the immune response to different arms of immunity.
Here, we discuss how targeting of hemagglutinin to MHC class II molecules increases
Th2 and IgG1 antibody responses, whereas targeting to chemokine receptors XCR1 or
CCR1/3/5 increases Th1 and IgG2a responses, in addition to CD8+ T cell responses.
We also discuss these results in relation to work published by others on APC-targeting.
Differential targeting of APC surface molecules may allow the induction of tailor-made
phenotypes of adaptive immune responses that are optimal for protection against various
infectious agents, including influenza virus.
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Influenza and the Need for Novel Vaccines
Annual influenza epidemics are caused by antigenic drift, whereby mutations in the major surface
proteins hemagglutinin (HA) and neuraminidase (NA) alter antigenic determinants. Consequently,
vaccines against seasonal influenza have to be annually updated in order to match the circulating
strains. On a more sporadic basis, new virions may form from reassortment, whereby antigenically
different strains combine to form a new subtype. Such an antigenic shift could result in a new
global pandemic. A wide selection of influenza A viruses continuously circulate in different species,
making accurate predictions of reassortments and pandemics challenging. On this backdrop, it is
important to develop vaccines that can offer broad protection against influenza, and that can be
rapidly manufactured.
Correlates of Protection
Antibodies
About 80% of the proteins that protrude from the viral influenza membrane are HAs (1, 2). During
infection, HA binds sialic acid residues on host cells to initiate virus–cell interactions and entry
of the viral capsid into the cytosol. The immunodominant antigenic determinants on HA are
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mostly located in close proximity to the sialic acid binding recep-
tor site, and represent mutation prone regions. Neutralizing anti-
bodies against HA can block viral entry into host cells, and confer
sterilizing immunity against influenza (3).
As induction of antibodies against HA is the focus of most
current influenza vaccine strategies, several studies have shown
that antibodies against NA may also be beneficial for clinical out-
come (4–6). Although unable to block viral infection, antibodies
against NA are thought to inhibit viral release from infected cells
(7). In addition, antibodies against the extracellular domain of
M2 have been shown to induce protection in animal models (8,
9). Whether anti-M2 antibodies are relevant in a human context
remains unclear (10, 11).
T Cells
In addition to antibodies, an influenza infection triggers the devel-
opment of virus-specific T cells. T cells can clear influenza infec-
tion in the absence of neutralizing antibodies (12, 13), and have in
the elderly population been found a good correlate of protection
(14). The ability to kill infected cells is mainly attributed to CD8+
T cells (15–17), and several of the CD8+ T cell subsets (Tc1,
Tc2, Tc17) have independently been shown capable of mediating
protection (18, 19). Typically, CD8+ cytotoxic T cells exert their
function by secreting perforin, the polymerization of which forms
a pore in the cell membrane that allows influx of serine proteases
(20, 21), or by direct Fas–Fas ligand interactions (22, 23).
The main function of CD4+ T cells during influenza infections
is to aid the development of cytotoxic T cells and antibodies (24,
25). The Th1 subtype of CD4+ T cells typically secrete interferon
γ (IFNγ), and is associated with cellular immunity. However, Th1
cells can in addition help B cells, and IFNγ causes a switch to
IgG2a. The hallmark cytokine of Th2 cells is interleukin 4 (IL4).
Th2 cells are excellent helpers of B cells, and IL4 causes a switch
to IgG1/IgE production (26). In accordance with the multiple
functions of CD4+ T cells, it has been shown that mice lacking
functional CD4+ T cells suffer more severe influenza infections,
and that the development of immunological memory is impaired
(27–29). In humans, pre-existing CD4+ T cells have been found to
be associated with lower viral shedding (30), and in mice, a subset
of CD4+ T cells that are able to directly lyse infected cells in a
perforin-dependent manner have been described (31).
Subunit Vaccines Against Influenza
Recently, a vaccine containing recombinant HA was licensed by
the US FDA, thus laying the foundation for future vaccines con-
taining recombinant influenza proteins (3). Subunit vaccines are
considered safe, as they do not contain live viral components.
However, a challenge of subunit vaccination is low immunogenic-
ity. Several immunizations are typically needed for efficacy, and
dose requirements are often high. These undesirable features have
warranted the development of more potent delivery methods and
adjuvants, which again could compromise the safety associated
with subunit vaccination.
Targeting of Antigen to APCs
The immunogenicity of subunit antigens can be increased by
targeted delivery of antigen to antigen presenting cells (APC). In
early studies, antigens were coupled to APC-specific antibodies by
chemical conjugation (32–34), but genetic conjugations are now
more common. Antigens can be linked directly to a Fab-fragment
(35), includedwithin loops of constant domains (36), or tail the C-
terminus of the antibody heavy chain (37). In all these cases (32–
37), the recombinant antibody-like molecules have APC-specific
V-regions.
We have previously generated novel vaccine molecules that
were designed to mimic the bivalent receptor binding capac-
ity of an antibody, display full-length antigens, and yet remain
smaller than an Ig molecule. To achieve this, a single chain
variable fragment (scFv) was linked to an antigen via the CH3-
domain of human IgG3 (38). The CH3-domains will dimerize
in the ER to generate bivalent display of antigens and scFvs
(Figure 1A). Immunization with such vaccine molecules contain-
ing scFvs directed againstmajor histocompatibility complexMHC
class II (MHC-II) molecules, and expressing HA, have recently
been shown to induce complete protection against influenza in
immunized mice (39).
FIGURE 1 | Immunization with APC-targeted dimeric vaccines protect
mice against influenza. (A) The vaccine molecules consist of targeting
units (scFv or natural ligands), dimerization units (hinge region and CH3
domain of human IgG3), and antigenic units [ex. influenza hemagglutinin
(HA)]. (B) BALB/c mice were immunized with 25µg DNA encoding the
indicated vaccine molecules [HA from A/California/07/2009 (H1N1)] targeted
toward MHC-II molecules (αMHCII-HA), chemokine receptors 1, 3, and 5
(MIP-1α-HA) or Xcr1 (Xcl1–HA). The mice were challenged 2weeks after a
single immunization with a lethal dose of influenza A/California/07/2009
(H1N1) and monitored for weight loss. All three APC-targeted vaccines
induced protection against influenza, in contrast to vaccination with HA alone
or NaCl. Modified with permission from Ref. (40).
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Natural ligands such as chemokines and toll like receptor (TLR)
agonists may specifically bind receptors that are preferentially
expressed on APCs. Thus, genetic fusion of antigen to natural lig-
ands has been evaluated as a method to increase immunogenicity
of subunit vaccination. A fusion between a tumor antigen and
chemokine CXCL10 or CCL7 has been demonstrated to increase
immune responses in immunized mice, and to protect against
tumor challenge (41). Similar targeting approaches have been
evaluated for influenza antigens, where the targeted delivery with
chemokines such as CCL3 or XCL1, or the TLR ligand flagellin,
have resulted in enhanced immunogenicity and protection against
influenza (40, 42, 43).
Traditionally, the main rationale behind targeting of antigens
to APCs has been to enhance antigen uptake and the subsequent
presentation to CD4+ and CD8+ T cells. Dendritic cells (DC)
are capable of efficient stimulation of both CD4+ and CD8+
T cells, and several APC targeting approaches have therefore
focused on this population of cells. DC were first described in
the 1970s (44), and are now generally divided into three sub-
classes based on ontogeny as well as functional and transcriptional
analysis (45). Plasmacytoid DC are highly efficient producers of
type I interferon in response toTLR triggering, while conventional
DC, cDC1 (Xcr1+Clec9a+), and cDC2 (CD11b+Sirp1a+) are the
main stimulators of T cell responses. Both cDC1 and cDC2 are
capable of presenting externally delivered antigen toCD4+ T cells,
but cDC1 is considered superior at cross-presentation to CD8+ T
cells (46, 47). Consequently, the specific targeting of antigen to
cDC1 has gained attention as a method for induction of CD8+ T
cell responses.
Polarization of Immune Responses
In a recent series of papers, we have evaluated the efficacy of
a single immunization with influenza HA targeted to MHC-
II molecules, chemokine receptors (CCR) 1, 3, and 5, or Xcr1
(39, 40, 42). For targeting of MHC-II molecules, HA was fused,
via a dimerization domain, to a scFv specific for murine I-Ed
(αMHCII-HA). Similarly, targeting to CCR1/3/5 and Xcr1 was
performed by fusing HA to the chemokines MIP-1α (MIP1α-
HA) or Xcl1 (Xcl1–HA), respectively. MHC-II molecules are
expressed on all professional APC, including B cells, macrophages
(MΦ), andDC. CCR1/3/5 are expressed onMΦ, DC, eosinophils,
and T cells, while Xcr1 is selectively expressed on cDC1 (48,
49). All three targeting approaches induced HA-specific immune
responses, and protected mice against a lethal challenge with
influenza virus (Figure 1B), in contrast to non-targeted controls
(39, 40, 42).
While conferring protection against influenza, targeted deliv-
ery of HA to MHC-II molecules, CCR1/3/5, or Xcr1 revealed
qualitative differences in induced immune responses. Targeting of
HA toMHC-IImolecules induced a Th2 dominant response char-
acterized by IL4-secreting CD4+ T cells, although some IFNγ+
T cells were also observed (39, 42). MIP1α-HA induced higher
numbers of IFNγ-secreting cells, and was found to polarize the
immune response toward Th1 cells (42). In an assessment of T cell
contribution to protection, depletion of CD8+ T cells in mice pre-
viously immunized with MIP1α-HA abolished protection against
influenza. By contrast, depletion of CD8+ and CD4+ T cells after
immunization with αMHCII-HA did not diminish the induced
protection (42). The importance of antibodies after immunization
withαMHCII-HAwas confirmed by the early presence of neutral-
izing antibodies in sera, and ultimately by the demonstration that
transfer of sera from immunized mice could protect naïve mice
against a lethal influenza challenge (39). It was also shown that
the fairly low amounts of T cells induced could confer protection
against influenza in the absence of relevant antibodies (39). Thus,
immunization with MIP1α-HA induces CD8+ T cell mediated
protection, while αMHCII-HA induces neutralizing antibodies
and T cells that probably act in concert.
MIP1α-HA targets several cell populations, whereas Xcl1-
targeted vaccines have been demonstrated to specifically bind
Xcr1 expressed on cDC1 (40). Adoptive transfer of OT-I and
OT-II cells to Xcr1 /  knockout or wild type mice, prior to
immunization with Xcl1–OVA, demonstrated that efficient pro-
liferation was dependent upon functional targeting of antigen to
Xcr1 (40). Similar observations have been made for Xcl1–OVA
delivered by laser-assisted intradermal delivery (50) or for OVA
directly fused to Xcl1 or to an antibody specific for Xcr1 (51).
Direct conjugation of antigen to Xcl1 was required for efficacy,
since delivery of unconjugated Xcl1 together with OVA failed to
enhance proliferation (50). The importance of a direct conjuga-
tion has also previously been demonstrated for antigen linked
to the chemokine MIP3α (52), and for a T cell epitope linked
to CD40-specific V regions (53). Together, these results indicate
that the observed immune responses are associated with receptor
uptake, rather than a chemokine induced adjuvant effect.
Similar to MIP1α-HA, vaccination with Xcl1–HA as DNA
induced a Th1 type of immunity, characterized by a marked
increase of IFNγ-secreting CD4+ T cells (40). Correspondingly,
Xcl1–HA induced cytotoxic CD8+ T cells that killed target
cells presenting HA-derived peptides on MHC class I molecules.
Depletion of Xcl1–HA-induced CD8+ T cells before viral chal-
lenge also confirmed that these cells played a central role in
mediating protection against influenza (40). Immunization with
Xcl1–OVA protein also resulted in the induction of cytotoxic
CD8+ T cell responses when administered i.v. in combination
with LPS (51). Interestingly, laser-assisted intradermal delivery
of Xcl1–OVA protein induced enhanced cytotoxic CD8+ T cell
responses in the absence of adjuvant (50). In both these studies,
targeting of OVA to the Xcr1 receptor induced protection in a
murine melanoma tumor model (50, 51). Taken together, these
three studies (40, 50, 51) highlight Xcr1 as a potent target for the
induction of cytotoxic CD8+ T cells.
Different types of immunity are associated with the induction
of different IgG subclasses. When CD4+ T cells provide help
to B cells, they also directly influence isotype switching. IFNγ
secreted by CD4+ Th1 cells will promote the secretion of IgG2a,
whereas IL4-secreting Th2 cells promote switching to IgG1 (54).
Consequently, an assessment of IgG1 vs IgG2a could indicate the
degree of induced Th1/Th2 immune polarization (Figure 2A).
As earlier mentioned, HA targeted to MHC-II molecules induced
higher levels of IL4 secreting CD4+ T cells, and strong antibody
responses. While such targeting increased responses for most
IgG subclasses, IgG1 was indeed dominant (39) (Figure 2A).
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FIGURE 2 | Targeting of selected surface receptors on APC will influence
the vaccine-induced Th1/Th2 polarization and antibody subtypes.
(A) Illustration of the different immune responses as induced by targeting of
antigen to the chemokine receptor Xcr1 (left side) or MHC-II (right side). Left
side: Targeting of antigen to Xcr1 induces IFNγ-secreting CD4+ Th1 cells that
can provide help to B cells and promote the formation of IgG2a antibodies. In
addition, targeting of Xcr1 results in presentation of peptides on MHC-I
molecules, and induction of strong CD8+ T cell responses. Right side: Targeting
of antigen to MHC-II molecules induces CD4+ Th2 cells that secrete IL4, and
that can provide help to B cells and promote the formation of IgG1 antibodies.
(B) BALB/c mice were immunized with 25µg DNA encoding the indicated
vaccine molecules [HA from influenza A/Puerto Rico/8/1934 (H1N1)], and
serums samples were harvested 2 or 10weeks after a single immunization.
Serum levels of HA-specific IgG1 and IgG2a antibodies were determined by
ELISA against inactivated influenza A/Puerto Rico/8/1934 (H1N1). Modified with
permission from Ref. (40).
Targeting of HA to Xcr1 also resulted in increased antibody
responses as compared to non-targeted controls, but these were
predominantly IgG2a (40) (Figure 2B). In contrast to Xcl1–HA,
MIP1α-HA induced a lower and more mixed humoral response,
with both IgG1 and IgG2a being present (42). It is likely that
the selective targeting of cDC1 cells caused a more stringently
Th1-polarized immune responses observed after vaccination with
Xcl1–HA, as opposed to the more mixed responses observed after
vaccination with MIP1α-HA. In summary, the three targeting
approaches induce different types of humoral responses, with
MHC-II-targeting promoting Th2/IgG1, CCR1,3,5-targeting giv-
ing a mixed IgG1/IgG2a response, and Xcr1-targeting polarizing
responses toward Th1/IgG2a (Figure 2B).
Interestingly, these observations suggest that the choice of APC
receptor may be used to direct immune responses toward partic-
ular antibody subclasses. This is of importance since the different
IgG subclasses vary in their ability to induce antibody dependent
cell-mediated cytotoxicity (ADCC) and complement activation,
partly through different affinities for FcγR [reviewed in Ref. (55)].
While IgG2a binds strongly to activating FcγR, such as FcγRI,
III, and IV, IgG1 have higher affinity for the inhibitory FcγRIIb
receptor (56). Consequently, IgG2a antibodies induce stronger
ADCC and complement activation than IgG1. Interestingly, two
recent studies have suggested that broadly neutralizing antibodies
against both HIV and influenza mediate their effect through FcγR
binding, and that antibodies of the IgG2a subclass therefore are
more efficient at this than IgG1 (57, 58). By contrast, strain-
specific neutralizing antibodies against HA do not require FcγR
binding, and function equally well as both IgG1 and IgG2a (58).
Since IgG2a antibodies induce stronger ADCC, they might also
be associated with an increased risk of induced cytopathic effects
to host cells (59). Thus, in situations where FcγR binding is not
required for induction of protection, it may be beneficial to induce
IgG1. All this considered, our results would suggest to target anti-
gens to MHC-II molecules for induction of specific neutralizing
anti-HA antibodies, whereas targeting to Xcr1 would be more
beneficial for induction of broadly neutralizing antibodies against
conserved HA epitopes, such as the stem.
Immune Polarization: A Function of
Targeted Receptor or the APC that
EXPRESS the Particular Receptor?
Since the targeted receptors are differently distributed on various
cell types, a relevant question is whether the targeted cell type
will determine the observed polarizations. Some studies have
focused on antibody-mediated targeting of Clec9A for vaccina-
tions (60–62). With its selective expression on cDC1 cells, the
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Clec9A-targeted approach is comparable to Xcl1–mediated deliv-
ery of antigen to Xcr1. Targeting of antigen to Clec9A has been
reported to enhance proliferation of antigen-specific CD4+ and
CD8+ T cells, and to confer protection against melanoma (60,
63). These observations correlate with our results in that Xcl1–HA
induced T cell-mediated protection against influenza. In addition,
targeting of Clec9A induced strong antibody responses, with an
efficient induction of T follicular helper cells (TFH) (61, 62).
Although themolecular mechanisms for howClec9A induce anti-
bodies are not known, TFH cells are presumably a key in that they
are important for germinal center (GC) formation and induction
of antibody secreting plasma cells (62). Interestingly, targeting of
antigen to Clec9a was reported to induce more IgG1 than IgG2a
(64), suggesting the induction of a more Th2 polarized CD4+ T
cell response. Together, this may suggest that it is the targeted
receptor, rather than the targeted APC type, that determine the
outcome of the immune response in these examples (40).
It should be noted that the studies targeting Clec9A and Xcr1
were done using different immunization protocols and different
mouse strains, raising the possibility that other factors have influ-
enced the results. However, experiments with targeting of Clec9A
showed Th2-like responses in Th1-prone C57BL/6J mice, and
targeting of antigen to Xcr1 induced Th1-polarization in both
Th2-prone BALB/c mice (40) and Th1-prone C57BL/6J mice (50,
51). Similarly, the Th2 polarization observed after targeting of HA
to MHC class II molecules has been confirmed in both BALB/c
and Th1-prone B10.D2 mice (39).
Receptor Expression and Endocytosis
The expression level of surface receptors and endocytosis rates
could play a major role in determining the efficacy by which
targeted vaccination stimulates presentation of peptides onMHC-
I/II to T cells. In a recent study, comparing targeting of antigen to
DEC205, Clec9a, CD11c, CD11b, and CD40, it was shown that
delivery to DEC205 resulted in about 80% of surface receptors
being internalized by 90min. By contrast, delivery to CD11c or
CD11b internalized surface receptors more slowly and inefficient
(65). The authors concluded that endosomal trafficking of endo-
cytosed antigen was likely to influence the efficacy of antigen pre-
sentation, a factor which has previously been suggested to influ-
ence cross-presentation to CD8+ T cells (66, 67). While endocy-
tosis is necessary for presentation of peptides from internalized
antigens toMHCI/II molecules, and thus also activation of T cells,
it is possible that reduced endocytosis might favor the stimulation
of B cells and antibody production by allowing an extended period
of time where B cells can recognize surface antigens.
Efficient Induction of Humoral Immune
Responses
Targeting of antigen to MHC-II molecules was shown early on
to increase serum responses in the absence of adjuvant (68). In
addition to the above mentioned studies targeting Clec9A, other
groups have identified CD11c and CD180 as particular interesting
receptors for induction of strong antibody responses (69–71).
CD11c is predominantly expressed on DC, with more minor
expression on monocytes, MΦ, neutrophils, and some B cells.
CD180 is expressed on B cells, DC, and MΦ.
Ligation of CD180 on B cells has been reported to induce
activation and proliferation, and may explain why targeting of
antigen to CD180 could activate CD4+ T cell-independent IgG
responses after immunizations of CD40-KO and TCR α/δ KO
mice (71–74). This is in contrast to our experiments with targeting
of HA to MHC-II molecules, since immunization of thymus-
deficient mice indicated that the humoral responses were T cell
dependent (39). The mechanism behind the strong antibody
responses induced by αMHCII-HA remains to be elucidated, but
the rapid formation of IgG in sera (day 8 after a single vac-
cination) points toward rapid affinity maturation and GC for-
mation. It is conceivable that the responses in this respect are
aided by the vaccine molecules forming an APC-B cell synapsis
(75, 76), where the bivalent vaccine molecules bridge MHC class
II molecules on APCs and antigen-specific B cell receptors on
B cells.
Conclusion
Wehave here discussed howproper selection of target receptors on
APCmay polarize immune responses toward either dominant cel-
lular or antibody responses. Furthermore, the immune responses
could be tailor-made with respect to IgG isotypes and Th1/Th2
dominance. Given the importance of neutralizing antibodies in
protection against influenza, targeting of antigen to MHC class
II molecules should be further evaluated in larger mammals and
humans. While antibodies against the influenza virus surface
proteins are important, T cell responses against the conserved
internal influenza antigens could offer broader protection. For
eliciting strong T cell responses, use of vaccine antigens that
are targeted by use of chemokines MIP-1α and Xcl1 could be
important. In the future, more APC targets for vaccines should
be tested for their ability to influence magnitude and polariza-
tion of immune responses. Also, a deeper understanding of the
relationship betweenAPC target specificity and immune response
polarization is needed.
References
1. Wrigley NG. Electron microscopy of influenza virus. Br Med Bull (1979)
35:35–8.
2. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum
haemagglutination-inhibiting antibody in protection against challenge infec-
tion with influenza A2 and B viruses. J Hyg (Lond) (1972) 70:767–77. doi:10.
1017/S0022172400022610
3. Reber A, Katz J. Immunological assessment of influenza vaccines and immune
correlates of protection. Expert Rev Vaccines (2013) 12:519–36. doi:10.1586/erv.
13.35
4. Kilbourne ED, Laver WG, Schulman JL, Webster RG. Antiviral activity of
antiserum specific for an influenza virus neuraminidase. J Virol (1968) 2:281–8.
5. Murphy BR, Kasel JA, Chanock RM. Association of serum anti-neuraminidase
antibody with resistance to influenza inman.NEngl J Med (1972) 286:1329–32.
doi:10.1056/NEJM197206222862502
Frontiers in Immunology | www.frontiersin.org July 2015 | Volume 6 | Article 3675
Grødeland et al. APC-targeting polarizes immune responses
6. Ogra PL, Chow T, Beutner KR, Rubi E, Strussenberg J, DeMello S, et al.
Clinical and immunologic evaluation of neuraminidase-specific influenza A
virus vaccine in humans. J Infect Dis (1977) 135:499–506. doi:10.1093/infdis/
135.4.499
7. Wohlbold TJ, Krammer F. In the shadow of hemagglutinin: a growing interest
in influenza viral neuraminidase and its role as a vaccine antigen.Viruses (2014)
6:2465–94. doi:10.3390/v6062465
8. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, JouWM, FiersW. A universal
influenza A vaccine based on the extracellular domain of the M2 protein. Nat
Med (1999) 5:1157–63. doi:10.1038/13484
9. Treanor JJ, Tierney EL, Zebedee SL, LambRA,Murphy BR. Passively transferred
monoclonal antibody to the M2 protein inhibits influenza A virus replication
in mice. J Virol (1990) 64:1375–7.
10. Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP. Antibody response to
the M2 protein of influenza A virus expressed in insect cells. J Gen Virol (1993)
74(Pt 1):143–6. doi:10.1099/0022-1317-74-1-143
11. Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, Wunner W,
et al. Influenza A virus infection engenders a poor antibody response against
the ectodomain of matrix protein 2. Virol J (2006) 3:102. doi:10.1186/
1743-422X-3-102
12. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to
influenza. N Engl J Med (1983) 309:13–7. doi:10.1056/NEJM198307073090103
13. Altenburg AF, Rimmelzwaan GF, de Vries RD. Virus-specific T cells as correlate
of (cross-)protective immunity against influenza. Vaccine (2015) 33:500–6.
doi:10.1016/j.vaccine.2014.11.054
14. McElhaney JE, Xie D, HagerWD, Barry MB,Wang Y, Kleppinger A, et al. T cell
responses are better correlates of vaccine protection in the elderly. J Immunol
(2006) 176:6333–9. doi:10.4049/jimmunol.176.10.6333
15. Bender BS, Croghan T, Zhang L, Small PA Jr. Transgenic mice lacking class I
major histocompatibility complex-restricted T cells have delayed viral clearance
and increased mortality after influenza virus challenge. J Exp Med (1992)
175:1143–5. doi:10.1084/jem.175.4.1143
16. van de Sandt CE, Kreijtz JH, de MG, Geelhoed-Mieras MM, Hillaire ML,
Vogelzang-van Trierum SE, et al. Human cytotoxic T lymphocytes directed to
seasonal influenza A viruses cross-react with the newly emerging H7N9 virus.
J Virol (2014) 88:1684–93. doi:10.1128/JVI.02843-13
17. Weinfurter JT, Brunner K, Capuano SV III, Li C, Broman KW, Kawaoka Y,
et al. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic
H1N1 influenza virus in nonhuman primates. PLoS Pathog (2011) 7:e1002381.
doi:10.1371/journal.ppat.1002381
18. Cerwenka A, Morgan TM, Harmsen AG, Dutton RW. Migration kinetics and
final destination of type 1 and type 2 CD8 effector cells predict protection
against pulmonary virus infection. J Exp Med (1999) 189:423–34. doi:10.1084/
jem.189.2.423
19. Hamada H, Garcia-HernandezML, Reome JB, Misra SK, Strutt TM,McKinstry
KK, et al. Tc17, a unique subset of CD8 T cells that can protect against lethal
influenza challenge. J Immunol (2009) 182:3469–81. doi:10.4049/jimmunol.
0801814
20. Liu CC,Walsh CM, Young JD. Perforin: structure and function. Immunol Today
(1995) 16:194–201. doi:10.1016/0167-5699(95)80121-9
21. Smyth MJ, Trapani JA. Granzymes: exogenous proteinases that induce target
cell apoptosis. Immunol Today (1995) 16:202–6. doi:10.1016/0167-5699(95)
80122-7
22. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is
mediated through perforin and Fas lytic pathways. Nature (1994) 370:650–2.
doi:10.1038/370650a0
23. Topham DJ, Tripp RA, Doherty PC. CD8+ T cells clear influenza virus by
perforin or Fas-dependent processes. J Immunol (1997) 159:5197–200.
24. Alam S, Sant AJ. Infection with seasonal influenza virus elicits CD4 T cells spe-
cific for genetically conserved epitopes that can be rapidly mobilized for protec-
tive immunity to pandemic H1N1 influenza virus. J Virol (2011) 85:13310–21.
doi:10.1128/JVI.05728-11
25. Topham DJ, Doherty PC. Clearance of an influenza A virus by CD4+ T cells is
inefficient in the absence of B cells. J Virol (1998) 72:882–5.
26. Pulendran B, Artis D. New paradigms in type 2 immunity. Science (2012)
337:431–5. doi:10.1126/science.1221064
27. Allan W, Tabi Z, Cleary A, Doherty PC. Cellular events in the lymph node and
lung ofmicewith influenza. Consequences of depletingCD4+T cells. J Immunol
(1990) 144:3980–6.
28. Anders EM, Peppard PM, Burns WH,White DO. In vitro antibody response to
influenza virus. I. T cell dependence of secondary response to hemagglutinin.
J Immunol (1979) 123:1356–61.
29. Riberdy JM, Christensen JP, Branum K, Doherty PC. Diminished primary and
secondary influenza virus-specific CD8(+) T-cell responses in CD4-depleted
Ig(-/-) mice. J Virol (2000) 74:9762–5. doi:10.1128/JVI.74.20.9762-9765.2000
30. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, et al.
Preexisting influenza-specific CD4+ T cells correlate with disease protection
against influenza challenge in humans.NatMed (2012) 18:274–80. doi:10.1038/
nm.2612
31. Brown DM, Dilzer AM, Meents DL, Swain SL. CD4 T cell-mediated protection
from lethal influenza: perforin and antibody-mediated mechanisms give a one-
two punch. J Immunol (2006) 177:2888–98. doi:10.4049/jimmunol.177.5.2888
32. Kawamura H, Berzofsky JA. Enhancement of antigenic potency in vitro and
immunogenicity in vivo by coupling the antigen to anti-immunoglobulin.
J Immunol (1986) 136:58–65.
33. Casten LA, Pierce SK. Receptor-mediated B cell antigen processing. Increased
antigenicity of a globular protein covalently coupled to antibodies specific for B
cell surface structures. J Immunol (1988) 140:404–10.
34. Snider DP, Segal DM. Targeted antigen presentation using crosslinked antibody
heteroaggregates. J Immunol (1987) 139:1609–16.
35. Baier G, Baier-Bitterlich G, Looney DJ, Altman A. Immunogenic targeting of
recombinant peptide vaccines to human antigen-presenting cells by chimeric
anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments
in vitro. J Virol (1995) 69:2357–65.
36. Lunde E, Munthe LA, Vabo A, Sandlie I, Bogen B. Antibodies engineered
with IgD specificity efficiently deliver integrated T-cell epitopes for antigen
presentation by B cells. Nat Biotechnol (1999) 17:670–5. doi:10.1038/10883
37. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic
cells induce peripheral T cell unresponsiveness under steady state conditions
in vivo. J Exp Med (2001) 194:769–79. doi:10.1084/jem.194.6.769
38. Fredriksen AB, Sandlie I, Bogen B. DNA vaccines increase immunogenicity of
idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting
cells.Mol Ther (2006) 13:776–85. doi:10.1016/j.ymthe.2005.10.019
39. Grodeland G, Mjaaland S, Roux KH, Fredriksen AB, Bogen B. DNA vaccine
that targets hemagglutinin toMHC class II molecules rapidly induces antibody-
mediated protection against influenza. J Immunol (2013) 191:3221–31. doi:10.
4049/jimmunol.1300504
40. Fossum E, Grodeland G, Terhorst D, Tveita AA, Vikse E, Mjaaland S, et al. Vac-
cine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8
T-cell responses against influenza virus. Eur J Immunol (2014) 45(2):624–35.
doi:10.1002/eji.201445080
41. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of
chemokines to a self tumor antigen induces protective, T-cell dependent anti-
tumor immunity. Nat Biotechnol (1999) 17:253–8. doi:10.1038/6995
42. Grodeland G, Mjaaland S, Tunheim G, Fredriksen AB, Bogen B. The specificity
of targeted vaccines for APC surfacemolecules influences the immune response
phenotype. PLoS One (2013) 8:e80008. doi:10.1371/journal.pone.0080008
43. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, et al. Potent
immunogenicity and efficacy of a universal influenza vaccine candidate com-
prising a recombinant fusion protein linking influenza M2e to the TLR5 ligand
flagellin. Vaccine (2008) 26:201–14. doi:10.1016/j.vaccine.2007.10.062
44. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral
lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp
Med (1973) 137:1142–62. doi:10.1084/jem.137.5.1142
45. Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, et al.
Dendritic cells, monocytes and macrophages: a unified nomenclature based on
ontogeny. Nat Rev Immunol (2014) 14:571–8. doi:10.1038/nri3712
46. Nair-Gupta P, Blander JM. An updated view of the intracellular mechanisms
regulating cross-presentation. Front Immunol (2013) 4:401. doi:10.3389/fimmu.
2013.00401
47. Pooley JL, Heath WR, Shortman K. Cutting edge: intravenous soluble antigen
is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8
T cells by CD8+ dendritic cells. J Immunol (2001) 166:5327–30. doi:10.4049/
jimmunol.166.9.5327
48. Crozat K, Tamoutounour S, Vu Manh TP, Fossum E, Luche H, Ardouin L,
et al. Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident
and migratory dendritic cells of the CD8{alpha}+ type. J Immunol (2011)
187:4411–5. doi:10.4049/jimmunol.1101717
Frontiers in Immunology | www.frontiersin.org July 2015 | Volume 6 | Article 3676
Grødeland et al. APC-targeting polarizes immune responses
49. Dorner BG, Dorner MB, Zhou X, Opitz C, Mora A, Guttler S, et al. Selective
expression of the chemokine receptor XCR1 on cross-presenting dendritic cells
determines cooperation with CD8+ T cells. Immunity (2009) 31:823–33. doi:10.
1016/j.immuni.2009.08.027
50. Terhorst D, Fossum E, Baranska A, Tamoutounour S, Malosse C, Garbani M,
et al. Laser-assisted intradermal delivery of adjuvant-free vaccines targeting
XCR1+ dendritic cells induces potent antitumoral responses. J Immunol (2015)
194(12):5895–902. doi:10.4049/jimmunol.1500564
51. Hartung E, Becker M, Bachem A, Reeg N, Jakel A, Hutloff A, et al. Induction
of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-
presenting dendritic cells in vivo via murine or human XCR1. J Immunol (2015)
194:1069–79. doi:10.4049/jimmunol.1401903
52. Schiavo R, Baatar D, Olkhanud P, Indig FE, Restifo N, Taub D, et al. Chemokine
receptor targeting efficiently directs antigens to MHC class I pathways and
elicits antigen-specific CD8+ T-cell responses. Blood (2006) 107:4597–605.
doi:10.1182/blood-2005-08-3207
53. Schjetne KW, Fredriksen AB, Bogen B. Delivery of antigen to CD40 induces
protective immune responses against tumors. J Immunol (2007) 178:4169–76.
doi:10.4049/jimmunol.178.7.4169
54. Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1
reciprocally regulate Ig isotype production. Science (1987) 236:944–7. doi:10.
1126/science.3107127
55. VidarssonG,Dekkers G, Rispens T. IgG subclasses and allotypes: from structure
to effector functions. Front Immunol (2014) 5:520. doi:10.3389/fimmu.2014.
00520
56. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcgammaRIV: a novel FcR
with distinct IgG subclass specificity. Immunity (2005) 23:41–51. doi:10.1016/j.
immuni.2005.05.010
57. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV.
Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for
in vivo activity. Cell (2014) 158:1243–53. doi:10.1016/j.cell.2014.08.023
58. DiLillo DJ, Tan GS, Palese P, Ravetch JV. Broadly neutralizing hemagglu-
tinin stalk-specific antibodies require FcgammaR interactions for protec-
tion against influenza virus in vivo. Nat Med (2014) 20:143–51. doi:10.1038/
nm.3443
59. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Comple-
ment activation plays a key role in the side-effects of rituximab treatment. Br J
Haematol (2001) 115:807–11. doi:10.1046/j.1365-2141.2001.03166.x
60. Caminschi I, Proietto AI, Ahmet F, Kitsoulis S, Shin TJ, Lo JC, et al. The
dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine
enhancement. Blood (2008) 112:3264–73. doi:10.1182/blood-2008-05-155176
61. Li J, Ahmet F, Sullivan LC, Brooks AG, Kent SJ, De RR, et al. Antibodies
targeting Clec9A promote strong humoral immunity without adjuvant in mice
and non-human primates. Eur J Immunol (2014) 45(3):854–64. doi:10.1002/eji.
201445127
62. Lahoud MH, Ahmet F, Kitsoulis S, Wan SS, Vremec D, Lee CN, et al. Targeting
antigen tomouse dendritic cells via Clec9A induces potent CD4T cell responses
biased toward a follicular helper phenotype. J Immunol (2011) 187:842–50.
doi:10.4049/jimmunol.1101176
63. Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, et al.
Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type
lectin. J Clin Invest (2008) 118:2098–110. doi:10.1172/JCI34584
64. Park HY, Light A, Lahoud MH, Caminschi I, Tarlinton DM, Shortman K.
Evolution of B cell responses to Clec9A-targeted antigen. J Immunol (2013)
191:4919–25. doi:10.4049/jimmunol.1301947
65. Reuter A, Panozza SE, Macri C, Dumont C, Li J, Liu H, et al. Criteria for
dendritic cell receptor selection for efficient antibody-targeted vaccination.
J Immunol (2015) 194(6):2696–705. doi:10.4049/jimmunol.1402535
66. Burgdorf S, Kautz A, Bohnert V, Knolle PA, Kurts C. Distinct pathways of
antigen uptake and intracellular routing in CD4 and CD8 T cell activation.
Science (2007) 316:612–6. doi:10.1126/science.1137971
67. Tacken PJ, Ginter W, Berod L, Cruz LJ, Joosten B, Sparwasser T, et al. Tar-
geting DC-SIGN via its neck region leads to prolonged antigen residence in
early endosomes, delayed lysosomal degradation, and cross-presentation. Blood
(2011) 118:4111–9. doi:10.1182/blood-2011-04-346957
68. Carayanniotis G, Barber BH. Adjuvant-free IgG responses inducedwith antigen
coupled to antibodies against class II MHC. Nature (1987) 327:59–61. doi:10.
1038/327059a0
69. Castro FV, Tutt AL, White AL, Teeling JL, James S, French RR, et al. CD11c
provides an effective immunotarget for the generation of both CD4 and CD8 T
cell responses. Eur J Immunol (2008) 38:2263–73. doi:10.1002/eji.200838302
70. White AL, Tutt AL, James S, Wilkinson KA, Castro FV, Dixon SV, et al. Ligation
of CD11c during vaccination promotes germinal centre induction and robust
humoral responses without adjuvant. Immunology (2010) 131:141–51. doi:10.
1111/j.1365-2567.2010.03285.x
71. Chaplin JW, Chappell CP, Clark EA. Targeting antigens to CD180 rapidly
induces antigen-specific IgG, affinity maturation, and immunological memory.
J Exp Med (2013) 210:2135–46. doi:10.1084/jem.20130188
72. ValentineMA, Clark EA, Shu GL, Norris NA, Ledbetter JA. Antibody to a novel
95-kDa surface glycoprotein on human B cells induces calcium mobilization
and B cell activation. J Immunol (1988) 140:4071–8.
73. Miura Y, Shimazu R, Miyake K, Akashi S, Ogata H, Yamashita Y, et al. RP105
is associated with MD-1 and transmits an activation signal in human B cells.
Blood (1998) 92:2815–22.
74. Chaplin JW, Kasahara S, Clark EA, Ledbetter JA. Anti-CD180 (RP105) activates
B cells to rapidly produce polyclonal Ig via a T cell and MyD88-independent
pathway. J Immunol (2011) 187:4199–209. doi:10.4049/jimmunol.1100198
75. Yuseff MI, Pierobon P, Reversat A, Lennon-Dumenil AM. How B cells capture,
process and present antigens: a crucial role for cell polarity. Nat Rev Immunol
(2013) 13:475–86. doi:10.1038/nri3469
76. Batista FD, Iber D, Neuberger MS. B cells acquire antigen from target cells after
synapse formation. Nature (2001) 411:489–94. doi:10.1038/35078099
Conflict of Interest Statement: Gunnveig Grødeland, Even Fossum, and Bjarne
Bogen are inventors on patent applications filed on the vaccine molecules by the
TTO offices of the University of Oslo and Oslo University Hospital, according to
institutional rules. Bjarne Bogen is head of the Scientific panel in Vaccibody AS.
Copyright © 2015 Grødeland, Fossum and Bogen. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org July 2015 | Volume 6 | Article 3677
